



File No. BIO/CT/23/000075

Dated 09-Oct-2023

To,

M/s CuraTeQ Biologics Private Ltd,  
Galaxy Floors 22-24, Survey No. 83/1,  
Hyderabad Knowledge City, Hyderabad,  
Telangana, (India) – 500081

Subject: Application for grant of permission to conduct Phase III clinical trial titled –“A Prospective, Randomized, Double Blind, Multicentric, Parallel Group Phase-III Clinical Study to Evaluate the Efficacy, Safety, Immunogenicity, Pharmacokinetics and Pharmacodynamics of BP16 Denosumab (60 mg/1ml single use Pre-filled Syringe) in Comparison to EU approved Prolia® (Denosumab, 60 mg/1ml single use Pre-filled Syringe) in Women with Postmenopausal Osteoporosis.” as per Protocol No.: ICS/CUR/2023-003, Version no 1.0 dated 16.05.2023 - regarding

Ref.: Your Application No. BIO/CT04/FF/2023/37716 dated 20-05-2023

Sir,

With reference to your Application No.: BIO/CT04/FF/2023/37716 dated 20-05-2023, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) The firm shall submit insurance certificate for the proposed clinical trial before initiation of the study.
- (II) The firm should submit the application for permission to manufacture and import the batches for CT purpose as per New Drugs and Clinical Trials Rules 2019
- (III) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (IV) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (V) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (VI) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (VII) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

- (VIII) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (IX) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (X) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (XI) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (XII) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XIII) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIV) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XV) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XVI) The laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XVII) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVIII) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XIX) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

**RAJEEV SINGH** Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: cn=IN, o=CENTRAL DRUGS STANDARD  
CONTROL ORGANIZATION, ou=RAJEEV SINGH  
RAGHUVANSHI,  
2.50.2-80c62f6a23e4afbf8a239774cdeb03c2  
7650410115a06564ef6754bd765dd1cb,  
postalCode=600034, st=TAMIL NADU,  
**RAGHU VANSI** c=IN, email=Rajeev.Singh@CDSCO.  
(Dr. Rajeev Singh Raghuwanshi) org, serial=D8F03BDC902  
0A7E73CA1D2761128CAB9FA701712A19013,  
cn=RAJEEV SINGH RAGHUVANSHI  
Digital Signature  
Date: 2023.11.11 12:00:00 +05'30'

**FORM CT-06**

(See rules 22, 25, 26, 29 and 30)

# PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licencing Authority hereby permits M/s CuraTeQ Biologics Private Ltd, Galaxy Floors 22-24, Survey No. 83/1, Hyderabad Knowledge City, Hyderabad, Telangana, (India) – 500081 to conduct clinical trial of the new drug or investigational new drug study titled “A Prospective, Randomized, Double Blind, Multicentric, Parallel Group Phase-III Clinical Study to Evaluate the Efficacy, Safety, Immunogenicity, Pharmacokinetics and Pharmacodynamics of BP16 Denosumab (60 mg/1ml single use Pre-filled Syringe) in Comparison to EU approved Prolia® (Denosumab, 60 mg/1ml single use Pre-filled Syringe) in Women with Postmenopausal Osteoporosis.” as per Protocol No.: ICS/CUR/2023-003, Version no 1.0 dated 16.05.2023, in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi  
Date: 09-Oct-2023

RAJEEV SINGH  
RAJEEV SINGH (Raghuvanshi)  
Drugs Controller General (India)  
Central Licensing Authority  
Stamp

**Annexure:****Details of new drug or investigational new drug:**

|                                                    |                                                                                                                                                                                                     |                 |                |
|----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------------|
| Names of the new drug or investigational new drug: | Denosumab 60 mg solution for injection in pre-filled syringe (r-DNA origin)                                                                                                                         |                 |                |
| Therapeutic class:                                 | RANKL Inhibitor                                                                                                                                                                                     |                 |                |
| Dosage form:                                       | Solution for injection in a single-dose prefilled syringes (PFS). Each pre-filled syringe contains 60 mg of Denosumab in 1 mL of solution (60 mg/mL) administered as a subcutaneous (SC) injection. |                 |                |
| Composition:                                       | Each PFS contains: -                                                                                                                                                                                |                 |                |
|                                                    | <b>Ingredient</b>                                                                                                                                                                                   | <b>Function</b> | <b>Qty/PFS</b> |
|                                                    | Denosumab IH                                                                                                                                                                                        | Active          | 60 mg          |
|                                                    | Glacial acetic acid USP                                                                                                                                                                             | Buffering Agent | 1.02 µL        |
|                                                    | Sorbitol USP-NF                                                                                                                                                                                     | Tonicity Agent  | 47 mg          |
|                                                    | Polysorbate 20 Ph.Eur., BP, JP, NF                                                                                                                                                                  | Stabilizer      | 0.1 mg         |
|                                                    | Water for Injection Ph. Eur. USP & IP                                                                                                                                                               | Vehicle         | q.s. to 1.0 mL |
| Indications:                                       | Postmenopausal Osteoporosis                                                                                                                                                                         |                 |                |

**Details of clinical trial site:**

| S. No. | Name and Address of Clinical Trial Site                                                                                                                            | Ethics Committee Details                                                                                                                                                           | Name of Principal Investigator |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| 1      | Great Eastern Medical School and Hospital, Ragolu Srikakulam, Andhra Pradesh 53248                                                                                 | Institutional Ethics Committee, Great Eastern Medical School and Hospital, Ragolu Srikakulam, Andhra Pradesh 53248<br><br>EC Reg. No.: ECR/1521/Inst/AP/2021                       | Dr. B Gowtham                  |
| 2      | Dept. of Orthopedic, SMS Medical College and attached hospital, J.L.N Road, 302004 Jaipur                                                                          | Ethics Committee of SMS Medical College, and attached hospital, J.L.N Road, 302004 Jaipur<br><br>EC Reg. No.: ECR/26/Inst/RJ/2013RR-19                                             | Dr. Ravindra Lamoriya          |
| 3      | Navneet Memorial Hospital "SUSHRUSHA" Opp. Sardar Patel Seva Samaj Hall, In Lane, Opp. Navrangpura Telephone exchange, Off C G road, Navrangpura, Ahmedabad 380009 | Sangini Hospital Ethics committee, Sangini Hospital, First floor, Santorini square, B/H Abhishree complex, Opp. Star Bazar, Nr. Jodhpur cross roads, Satellite, Ahmedabad - 380015 | Dr. Dhaval Patel               |

|  |  |                                         |  |
|--|--|-----------------------------------------|--|
|  |  | EC Reg. No.: ECR/147/Inst/GJ/2013/RR-19 |  |
|--|--|-----------------------------------------|--|

